<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Background: Platelet-rich plasma (PRP) and hyaluronic acid (HA) are injectable treatments for knee osteoarthritis. The focus of previous studies has compared their efficacy against each other as monotherapy. However, a new trend of combining these 2 injections has emerged in an attempt to have a synergistic effect. Purpose: To systematically review the clinical literature examining the combined use of PRP + HA. Design: Systematic review. Methods: A systematic review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines using PubMed and Embase. The following search terms were used: knee osteoarthritis AND platelet rich plasma AND hyaluronic acid. The review was performed by 2 independent reviewers who applied the inclusion/exclusion criteria and independently extracted data, including methodologic scoring, PRP preparation technique, HA composition, and patient-reported outcomes (PROs). Results: A total of 431 articles were screened, 12 reviewed in full, and 8 included in the final analysis: 2 case series, 3 comparative, and 3 randomized studies. Average follow-up was 9 months. The modified Coleman Methodology Score was 38.13 ± 13.1 (mean ± SD). Combination therapy resulted in improved PROs in all studies. Of the comparative and randomized studies, 2 demonstrated that combination therapy was superior to HA alone. However, when PRP alone was used as the control arm (4 studies), combination therapy was not superior to PRP alone. Conclusion: Combination therapy with PRP + HA improves PROs and is superior to HA alone but is not superior to PRP alone.

Download Full-text

STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer

Cellular Immunology ◽

10.1016/j.cellimm.2021.104384 ◽

2021 ◽

pp. 104384

Author(s):

Jiaqi Shi ◽

Caiqi Liu ◽

Shengnan Luo ◽

Tingyu Cao ◽

Binlin Lin ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Tumor Progression ◽

Murine Models ◽

Inhibitor Combination

Download Full-text

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

BMC Gastroenterology ◽

10.1186/s12876-021-01771-z ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Kiyoaki Sugiura ◽

Yuki Seo ◽

Takayuki Takahashi ◽

Hideyuki Tokura ◽

Yasuhiro Ito ◽

...

Keyword(s):

Colorectal Cancer ◽

Health Care ◽

Sensitivity Analysis ◽

Cost Effectiveness ◽

Combination Therapy ◽

Metastatic Colorectal Cancer ◽

Cost Effective ◽

Model Parameters ◽

Combination Regimen ◽

The Cost

Abstract Background TAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence supporting its use for this indication is limited. We compared the cost-effectiveness of TAS-102 plus bevacizumab combination therapy with TAS-102 monotherapy for patients with chemorefractory metastatic colorectal cancer. Method Markov decision modeling using treatment costs, disease-free survival, and overall survival was performed to examine the cost-effectiveness of TAS-102 plus bevacizumab combination therapy and TAS-102 monotherapy. The Japanese health care payer’s perspective was adopted. The outcomes were modeled on the basis of published literature. The incremental cost-effectiveness ratio (ICER) between the two treatment regimens was the primary outcome. Sensitivity analysis was performed and the effect of uncertainty on the model parameters were investigated. Results TAS-102 plus bevacizumab had an ICER of $21,534 per quality-adjusted life-year (QALY) gained compared with TAS-102 monotherapy. Sensitivity analysis demonstrated that TAS-102 monotherapy was more cost-effective than TAS-102 and bevacizumab combination therapy at a willingness-to-pay of under $50,000 per QALY gained. Conclusions TAS-102 and bevacizumab combination therapy is a cost-effective option for patients who have metastatic colorectal cancer in the Japanese health care system.

Download Full-text

Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3109-4 ◽

2016 ◽

Vol 78 (3) ◽

pp. 585-593 ◽

Cited By ~ 3

Author(s):

Takao Takahashi ◽

◽

Yasunori Emi ◽

Eiji Oki ◽

Kazuma Kobayashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Exon 2 ◽

Multicenter Phase ◽

Previously Treated ◽

Kras Exon

Download Full-text

The Combination of Zerumbone and 5-FU: A Significant Therapeutic Strategy in Sensitizing Colorectal Cancer Cells to Treatment

BioMed Research International ◽

10.1155/2021/6635874 ◽

2021 ◽

Vol 2021 ◽

pp. 1-18

Author(s):

Razieh Dehghan ◽

Fatemeh Bahreini ◽

Rezvan Najafi ◽

Massoud Saidijam ◽

Razieh Amini

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Colony Formation ◽

Survival Rates ◽

Scratch Test ◽

Protein Levels ◽

Inhibitory Function ◽

Gene And Protein Expression ◽

Hct 116 ◽

Hct 116 Cells

Objectives. Chemotherapy is considered to be essential in the treatment of patients with colorectal cancer (CRC), but drug resistance reduces its efficacy. Many patients with advanced CRC eventually show resistance to 5-fluorouracil (5-FU) therapy. Synergistic and potentiating effects of combination therapy, using herbal and chemical drugs, can improve patients’ response. Zerumbone (ZER), which is derived from ginger, has been studied for its growth inhibitory function in various types of cancer. Methods. The cytotoxic effects of ZER and 5-FU alone and their combination, on the SW48 and HCT-116 cells, were examined, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). The mRNA and protein levels of β-catenin, survivin, and vimentin were measured in treated CRC cells, using qRT-PCR and western blot. Colony formation assay, scratch test, and flow cytometry were performed to detect the changes of proliferation, migration, and apoptosis. Key Findings. In HCT-116- and SW48-treated cells, the proliferation, the gene and protein expression levels of the markers, the migration, the colony formation, and the survival rates were all significantly reduced compared to the control groups, and the sharpest decline was observed in the 5-FU+ZER treatment groups. Conclusions. Combination therapy has shown promising results in CRC cells, especially in drug-resistant cells.

Download Full-text